Wall Street analysts expect AMETEK, Inc. (NYSE:AME) to post earnings per share (EPS) of $0.78 for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for AMETEK’s earnings. The lowest EPS estimate is $0.78 and the highest is $0.80. AMETEK reported earnings of $0.66 per share in the same quarter last year, which would indicate a positive year over year growth rate of 18.2%. The business is scheduled to announce its next quarterly earnings report on Thursday, November 1st.

On average, analysts expect that AMETEK will report full year earnings of $3.21 per share for the current fiscal year, with EPS estimates ranging from $3.19 to $3.24. For the next financial year, analysts forecast that the business will post earnings of $3.53 per share, with EPS estimates ranging from $3.44 to $3.61. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AMETEK.

AMETEK (NYSE:AME) last issued its earnings results on Tuesday, July 31st. The technology company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.05. AMETEK had a net margin of 16.65% and a return on equity of 16.94%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the prior year, the business earned $0.65 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis.

Several equities analysts recently commented on AME shares. Cowen reaffirmed a “buy” rating and issued a $85.00 price objective on shares of AMETEK in a research report on Sunday, August 12th. ValuEngine raised shares of AMETEK from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Bank of America increased their price objective on shares of AMETEK from $87.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, August 1st. Royal Bank of Canada reaffirmed a “buy” rating and issued a $86.00 price objective on shares of AMETEK in a research report on Wednesday, August 1st. Finally, Morgan Stanley increased their price objective on shares of AMETEK from $79.00 to $84.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 1st. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. AMETEK currently has a consensus rating of “Buy” and an average price target of $86.08.

In other AMETEK news, insider John Wesley Hardin sold 29,955 shares of the firm’s stock in a transaction that occurred on Wednesday, September 19th. The shares were sold at an average price of $81.55, for a total transaction of $2,442,830.25. Following the completion of the transaction, the insider now directly owns 70,016 shares of the company’s stock, valued at approximately $5,709,804.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gretchen W. Mcclain sold 3,870 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $80.00, for a total transaction of $309,600.00. Following the transaction, the director now directly owns 8,018 shares of the company’s stock, valued at $641,440. The disclosure for this sale can be found here. Insiders have sold a total of 66,925 shares of company stock valued at $5,334,720 over the last three months. 2.10% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of AME. BlackRock Inc. raised its position in AMETEK by 11.8% during the 2nd quarter. BlackRock Inc. now owns 18,178,345 shares of the technology company’s stock worth $1,311,749,000 after buying an additional 1,922,878 shares during the last quarter. Millennium Management LLC raised its position in AMETEK by 169.1% during the 2nd quarter. Millennium Management LLC now owns 1,647,306 shares of the technology company’s stock worth $118,870,000 after buying an additional 1,035,084 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in AMETEK by 163.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,093,946 shares of the technology company’s stock worth $83,106,000 after buying an additional 679,049 shares during the last quarter. Renaissance Technologies LLC purchased a new position in AMETEK during the 2nd quarter worth approximately $40,825,000. Finally, BNP Paribas Arbitrage SA raised its position in AMETEK by 714.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 610,418 shares of the technology company’s stock worth $44,048,000 after buying an additional 535,447 shares during the last quarter. 85.11% of the stock is owned by institutional investors.

Shares of NYSE:AME traded up $0.15 during trading on Tuesday, reaching $81.53. The stock had a trading volume of 1,507,194 shares, compared to its average volume of 1,003,509. AMETEK has a one year low of $64.81 and a one year high of $81.92. The stock has a market capitalization of $18.91 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.32 and a beta of 1.21. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.19 and a current ratio of 1.71.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 14th will be given a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Thursday, September 13th. AMETEK’s dividend payout ratio is presently 21.46%.

About AMETEK

AMETEK, Inc manufactures and sells electronic instruments and electromechanical devices worldwide. Its Electronic Instruments Group segment offers advanced instruments for the process, power and industrial, and aerospace markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage markets; and instruments for the laboratory equipment, ultraprecision manufacturing, medical, and test and measurement markets.

Read More: Dividend

Get a free copy of the Zacks research report on AMETEK (AME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMETEK (NYSE:AME)

Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.